ENVISIA THERAPEUTICS RELEASES INTERIM ENV515 (travoprost XR) PHASE 2 DATA DEMONSTRATING 11-MONTH DURATION-OF-ACTION AFTER A SINGLE DOSE IN PATIENTS WITH GLAUCOMA

ENVISIA THERAPEUTICS RELEASES INTERIM ENV515 (travoprost XR) PHASE 2 DATA DEMONSTRATING 11-MONTH DURATION-OF-ACTION AFTER A SINGLE DOSE IN PATIENTS WITH GLAUCOMA

Results Provide Encouraging Outlook for Extended Treatment of Glaucoma Patients

RESEARCH TRIANGLE PARK, NC – FEBRUARY 3, 2017 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial in patients with glaucoma showing a clinically meaningful reduction in intraocular pressure (IOP) for the entire 11-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the leading cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. Read more here.

Copyright 2013 Envisia Therapeutics